＜4586＞ Medlec 118 +2
backlash. The operating profit and loss forecast for the fiscal year ending 24/12 has been revised upward from the previous deficit of 1,425 billion yen to a deficit of 1,183 billion yen (deficit of 933 million yen in the previous fiscal year results). This is because favorable pharmacokinetics and tolerability were shown in clinical phase 1 trials of the new drug candidate “Alto-101” in the central nervous system area, development milestones stipulated in a partnership agreement with the US drug discovery venture Alto have been achieved, and milestone income and clinical trial drug supply for a fee are expected.
＜4479＞ McUake 685 -20
The decline continued drastically. The cumulative operating profit and loss for the 2nd quarter of the fiscal year ending 24/9 (23/10/24 to 3/24) was announced as a deficit of 98 million yen (deficit of 378 million yen in the same period last year). Thoroughly controlling sales and administration costs, such as advertising expenses, etc., and trying to improve cost effectiveness was successful. The full-year forecast remained unchanged with a surplus of 0.16 million yen. Although the deficit for the first half has shrunk compared to the same period last year, according to explanatory materials, it is said that “the scale of operating losses exceeded the plan in a single quarter due to a decline in the top line,” and sales are ahead.
＜4316＞ BeMap 494 +80
Stop height. It has been announced that development of an AI model that detects analysis results different from usual by storing and analyzing power data, which is the core of the “monitoring service for utilizing electricity usage data,” which was carried out with the University of Tokyo and 2 venture companies from Tokyo University of Science, has been completed. In order to monitor the health of seniors and single families, check the electricity usage status of smart meters that digitally measure electricity usage. In the future, provision of services will begin sequentially as soon as adjustments with partner companies have been completed.
＜4591＞ ribomic 84 +1
Continued increase for 3 days. It has been announced to the Japanese Patent Office that a patent application relating to a conjugate (complex formation by chemical bonding) between aptamer and polyethyloxazoline and extending its half-life in blood has been completed. It was discovered that the conjugate of aptamer and polyethyloxazoline shows excellent internal dynamics and is an alternative compound for polyethylene glycol (PEG). Quality control of compounds is easy, and it is expected that they will be supplied at low cost in the future.
＜9166＞ GENDA 3295 +225
A significant increase of 3 days. It has been announced that 5/31 will be split at a ratio of 2 shares per share using 5/31 as the reference date. The purpose is to reduce the amount of money per investment unit, create an environment where it is easy to invest, improve the liquidity of the company's stock, and expand the investor base. At the same time, part of the Articles of Incorporation will be changed, and the total number of shares that can be issued will be raised from 127 million shares to 255 million shares. Also, it has been clarified that consolidated subsidiaries will make the amusement facility businesses Amex (Gifu City) and Plebi (Hitachi City, Ibaraki Prefecture) wholly owned subsidiaries.
＜5131＞ Linkers 220 +50
The stop is high. A business alliance has been formed with Ondec ＜7360＞, and it has been announced that they will cooperate with each other in the 3 areas of M&A support, platform development, and business matching. In addition to cooperatively developing M&A advisory services in the manufacturing field, they also provide Linkers' technology matching know-how and knowledge through platform development related to corporate alliances being promoted by Ondec. Also, Linkers' SaaS type business matching system “LFB” will be introduced on-deck.